Investigational drug · Phase 3
HMPL-453
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "HMPL-453"
First trial start
2020
Sep 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMPL-453", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Intrahepatic Cholangiocarcinoma
- Solid Tumor, Adult
- Solid Tumor
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HMPL-453" as an intervention, largest first.
- HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaPivotal-lookingRecruiting
HutchmedIndustry
NCT04353375 · 235 participants (planned) · Start Sep 3, 2020 · Primary completion Jun 30, 2028
Drug: HMPL-453 · For: Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult
Sites: Beijing, China
Hutchison Medipharma LimitedIndustry
NCT05173142 · 190 participants · Start Jan 22, 2022 · Primary completion Jul 17, 2025
Drug: HMPL-453; gemcitabine and cisplatin and 2 more · For: Solid Tumor
Sites: Beijing, China
HutchmedIndustry
NCT07697157 · 40 participants · Start Mar 1, 2025 · Primary completion Dec 31, 2025
Drug: HMPL-453 with Itraconazole; HMPL-453 with Rifampin · For: Health, Subjective
Sites: Wuhu, China
Hutchison Medipharma LimitedIndustry
NCT03160833 · 33 participants · Start May 23, 2017 · Primary completion Dec 31, 2019
Drug: HMPL-453 · For: Solid Tumor, Adult
Sites: Beijing, China; Guangzhou, China
- HMPL-453 in Advanced Malignant MesotheliomaStatus unknown
Hutchison Medipharma LimitedIndustry
NCT04290325 · 27 participants (planned) · Start Dec 30, 2019 · Primary completion Nov 30, 2022
Drug: HMPL-453 · For: Advanced Malignant Mesothelioma
Sites: Shanghai, China
HutchmedIndustry
NCT05930119 · 24 participants · Start Mar 17, 2023 · Primary completion Aug 28, 2023
Drug: HMPL-453; Rabeprazole · For: Intrahepatic Cholangiocarcinoma
Sites: Shanghai, China
Hutchison Medipharma LimitedIndustry
NCT02966171 · 14 participants · Start Jan 2017 · Primary completion Aug 23, 2018
Drug: HMPL-453 · For: Solid Tumor
Sites: Sydney, Australia; Frankston, Australia; Melbourne, Australia · 4 sites in all
HutchmedIndustry
NCT07644442 · 6 participants · Start Feb 26, 2025 · Primary completion Mar 14, 2025
Drug: HMPL-453 · For: Mass Balance Study
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Intrahepatic Cholangiocarcinoma
- Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials
CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.